Igor Richter1,2,3, Alexandr Poprach4,5, Anezka Zemankova6, Tomas Buchler2, Jiri Bartos1, Vladimir Samal7, Hana Studentova6, Aneta Rozsypalova2, Josef Dvorak2, Ondrej Brom8, Bohuslav Melichar6. 1. Department of Oncology, Regional Hospital Liberec, Czech Republic. 2. Department of Oncology, First Faculty of Medicine, Charles University and Thomayer Hospital, Prague, Czech Republic. 3. Technical University of Liberec, Czech Republic. 4. Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic. 5. Department of Comprehensive Cancer Care, Faculty of Medicine, Masaryk University, Brno, Czech Republic. 6. Department of Oncology, Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital Olomouc, Czech Republic. 7. Department of Urology, Regional Hospital Liberec, Czech Republic. 8. ACREA, Czech Republic.
Abstract
AIM: The aim of this study was to retrospectively analyze treatment outcomes and tolerance in patients in whom cabozantinib was used after previous targeted therapy. PATIENTS AND METHODS: Cabozantinib was administered in dose 60 mg/day, a subset of patients received initial dose of 40 mg/day. The treatment was administered until to progression or unacceptable toxicity. CT scans were assessed according to the RECIST 1.1 and toxicity of treatment was assessed based on the CTCAE (version 4). Kaplan-Meier analysis was used to calculate progression free survival (PFS) and overall survival (OS). We performed a multivariate analysis of risk factors for treatment outcomes (PFS, OS) by Cox regression analysis. All statistics were evaluated at the significance level alpha = 0.05. RESULTS: 54 patients with metastatic renal cell carcinoma (mRCC) were evaluated. Median PFS in all patients treated with cabozantinib was 9.3 months (95% CI 5.3 - 13.3). One-year survival was 85.2% (95% CI 72.9 - 93.4%). Treatment response was observed in 45.9% of cases, including one complete remission. Cox regression analysis demonstrated that presence of subsequent treatment was the only factor with a significant effect on OS (P=0.008). Adverse events occurred in 88.9% of patients, grade 3 - 4 in 46.3%. CONCLUSION: The analysis of our cohort of patients treated with cabozantinib in the second or higher lines of treatment showed that cabozantinib represents an effective and safe therapy and contributes to longer survival of our mRCC patients.
AIM: The aim of this study was to retrospectively analyze treatment outcomes and tolerance in patients in whom cabozantinib was used after previous targeted therapy. PATIENTS AND METHODS: Cabozantinib was administered in dose 60 mg/day, a subset of patients received initial dose of 40 mg/day. The treatment was administered until to progression or unacceptable toxicity. CT scans were assessed according to the RECIST 1.1 and toxicity of treatment was assessed based on the CTCAE (version 4). Kaplan-Meier analysis was used to calculate progression free survival (PFS) and overall survival (OS). We performed a multivariate analysis of risk factors for treatment outcomes (PFS, OS) by Cox regression analysis. All statistics were evaluated at the significance level alpha = 0.05. RESULTS: 54 patients with metastatic renal cell carcinoma (mRCC) were evaluated. Median PFS in all patients treated with cabozantinib was 9.3 months (95% CI 5.3 - 13.3). One-year survival was 85.2% (95% CI 72.9 - 93.4%). Treatment response was observed in 45.9% of cases, including one complete remission. Cox regression analysis demonstrated that presence of subsequent treatment was the only factor with a significant effect on OS (P=0.008). Adverse events occurred in 88.9% of patients, grade 3 - 4 in 46.3%. CONCLUSION: The analysis of our cohort of patients treated with cabozantinib in the second or higher lines of treatment showed that cabozantinib represents an effective and safe therapy and contributes to longer survival of our mRCC patients.
Authors: Rana R McKay; Nils Kroeger; Wanling Xie; Jae-Lyun Lee; Jennifer J Knox; Georg A Bjarnason; Mary J MacKenzie; Lori Wood; Sandy Srinivas; Ulka N Vaishampayan; Sun-Young Rha; Sumanta K Pal; Frede Donskov; Srinivas K Tantravahi; Brian I Rini; Daniel Y C Heng; Toni K Choueiri Journal: Eur Urol Date: 2013-08-15 Impact factor: 20.096
Authors: L Zhou; X-D Liu; M Sun; X Zhang; P German; S Bai; Z Ding; N Tannir; C G Wood; S F Matin; J A Karam; P Tamboli; K Sircar; P Rao; E B Rankin; D A Laird; A G Hoang; C L Walker; A J Giaccia; E Jonasch Journal: Oncogene Date: 2015-09-14 Impact factor: 9.867
Authors: Josef Dvorak; Dimitar Hadzi Nikolov; Ladislav Dusek; Alzbeta Filipova; Igor Richter; David Buka; Ales Ryska; Jaroslav Mokry; Stanislav Filip; Bohuslav Melichar; Tomas Buchler; Jitka Abrahamova Journal: J BUON Date: 2017 Nov-Dec Impact factor: 2.533
Authors: Daniel J George; Colin Hessel; Susan Halabi; M Dror Michaelson; Olwen Hahn; Meghara Walsh; Joel Picus; Eric J Small; Shaker Dakhil; Darren R Feldman; Milan Mangeshkar; Christian Scheffold; Michael J Morris; Toni K Choueiri Journal: Oncologist Date: 2019-08-09